(Q33529769)

27 July 2017

title

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy (English)

1 reference

proliferative diabetic retinopathy

27 July 2017

1 reference

1 reference

1 reference

Raffaello di Lauro

1

1 reference

27 July 2017

Pio De Ruggiero

2

1 reference

27 July 2017

Raffaella di Lauro

3

1 reference

27 July 2017

Maria Teresa di Lauro

4

1 reference

27 July 2017

Mario Rosario Romano

5

1 reference

27 July 2017

publication date

5 February 2010

1 reference

Graefe's Archive for Clinical and Experimental Ophthalmology

27 July 2017

published in

1 reference

27 July 2017

volume

248

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

785-791

1 reference

https://scigraph.springernature.com/pub.10.1007/s00417-010-1303-3

27 July 2017

exact match

0 references

cites work

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

2 references

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

21 January 2018

12 December 2020

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

The role of bevacizumab as first-line therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1303-3

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

1 reference

12 December 2020

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema

1 reference

12 December 2020

Increased expression of angiogenic growth factors in age-related maculopathy

1 reference

12 December 2020

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

12 December 2020

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

12 December 2020

The role of vascular endothelial growth factor in ocular health and disease

1 reference

12 December 2020

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans

1 reference

12 December 2020

Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

1 reference

12 December 2020

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

1 reference

12 December 2020

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

1 reference

12 December 2020

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

12 December 2020

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

1 reference

12 December 2020

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

1 reference

12 December 2020

Pegaptanib for neovascular age-related macular degeneration

1 reference

12 December 2020

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

1 reference

12 December 2020

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab

1 reference

12 December 2020

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

1 reference

12 December 2020

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

1 reference

12 December 2020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

12 December 2020

Ranibizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

12 December 2020

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

1 reference

12 December 2020

Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion

1 reference

12 December 2020

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity

1 reference

12 December 2020

Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story

1 reference

12 December 2020

Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

12 December 2020

Relationships between the endothelin and nitric oxide pathways

1 reference

12 December 2020

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection

1 reference

12 December 2020

Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma

1 reference

12 December 2020

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

1 reference

12 December 2020

Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes

1 reference

12 December 2020

Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

12 December 2020

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

1 reference

12 December 2020

Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

12 December 2020

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

1 reference

12 December 2020

10.1007/S00417-010-1303-3

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1010181233

0 references

1 reference